Linked Data API

Show Search Form

Search Results

229259
registered interest false more like this
date less than 2015-03-23more like thismore than 2015-03-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Eyesight: Testing more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how many free sight tests were provided on the NHS to people aged (a) under and (b) over 60 in England in each of the last five years. more like this
tabling member constituency Leicester West remove filter
tabling member printed
Liz Kendall more like this
uin 228835 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-26more like thismore than 2015-03-26
answer text <p>The table below shows how many National Health Service funded sight tests were provided in England to people aged over 60 and to other eligible groups in each of the last five years.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td><p>Aged 60 and over</p></td><td><p>5,191,773</p></td><td><p>5,305,177</p></td><td><p>5,537,930</p></td><td><p>5,480,711</p></td><td><p>5,562,847</p></td></tr><tr><td><p>Other eligible groups</p></td><td><p>6,619,878</p></td><td><p>6,633,352</p></td><td><p>6,767,797</p></td><td><p>6,858,542</p></td><td><p>7,224,583</p></td></tr><tr><td><p>Total</p></td><td><p>11,811,651</p></td><td><p>11,938,529</p></td><td><p>12,305,727</p></td><td><p>12,339,253</p></td><td><p>12,787,430</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source:</em> Health and Social Care Information Centre</p><p> </p><p> </p><p> </p><p>Free sight tests on the NHS are available to certain eligible groups including people aged 60 and over, children under 16, those aged 16-18 in full-time education, people on low incomes and defined categories of people at particular risk of developing eye disease.</p><p> </p><p> </p><p> </p><p>Some individuals may qualify for an NHS sight test on more than one criterion. However, they would only be recorded against one criterion on the NHS sight test form. Patients are more likely to be recorded according to their clinical need rather than their age. For example, a patient aged over 60, with glaucoma is likely to be recorded in the glaucoma category only. The count for those aged 60 and over is therefore an approximate figure and may slightly underestimate.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-03-26T11:14:53.9Zmore like thismore than 2015-03-26T11:14:53.9Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4026
label Biography information for Liz Kendall more like this
228806
registered interest false more like this
date less than 2015-03-20more like thisremove minimum value filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Chronic Obstructive Pulmonary Disease more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much was spent on the prescription of drugs to manage chronic obstructive pulmonary disease in the NHS in each year from 2009-10 to 2014-15. more like this
tabling member constituency Leicester West remove filter
tabling member printed
Liz Kendall more like this
uin 228591 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-25more like thismore than 2015-03-25
answer text <p>The information requested cannot be provided as information on why a drug is prescribed is not collected. This is a particular issue for chronic obstructive pulmonary disease (COPD) as medicines used to treat COPD are also used to treat a number of other medical conditions, for example asthma.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-03-25T17:26:42.35Zmore like thismore than 2015-03-25T17:26:42.35Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4026
label Biography information for Liz Kendall more like this
228871
registered interest false more like this
date less than 2015-03-20more like thisremove minimum value filter
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health remove filter
hansard heading Chronic Obstructive Pulmonary Disease more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much the Government has allocated to development of new drugs and treatments for chronic obstructive pulmonary disease each year from 2009-10 to 2014-15. more like this
tabling member constituency Leicester West remove filter
tabling member printed
Liz Kendall more like this
uin 228612 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2015-03-25more like thismore than 2015-03-25
answer text <p>The following table shows estimated expenditure on research relating to the development of new drugs and treatments for chronic obstructive pulmonary disease (COPD) by Research Councils, Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p>£ million</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td></tr><tr><td><p>Biotechnology and Biological Sciences Research Council (BBSRC)</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Medical Research Council (MRC)</p></td><td><p>3.8</p></td><td><p>2.6</p></td><td><p>2.4</p></td><td><p>2.9</p></td><td><p>2.1</p></td><td><p>n/a</p></td></tr><tr><td><p>Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.3</p></td><td><p>1.3</p></td><td><p>1.4</p></td><td><p>0.6</p></td></tr><tr><td><p>NIHR</p></td><td><p>0.9</p></td><td><p>0.8</p></td><td><p>0.9</p></td><td><p>1.9</p></td><td><p>2.6</p></td><td><p>2.5</p></td></tr><tr><td><p>Total</p></td><td><p>4.7</p></td><td><p>3.5</p></td><td><p>3.7</p></td><td><p>6.2</p></td><td><p>6.1</p></td><td><p>n/a</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><p>1. The BBSRC funds world class bioscience and biotechnology that underpins health research funded by others, but does not fund research directly relating to understanding/treating specific diseases. The underpinning health research that the BBSRC supports seeks to provide a better understanding of what makes a healthy biological system, and the key moderators of this health (both positive and negative), and also informs strategies to help maintain resilient health across the life-course and reduce the risk of emergence of diseases typically associated with age-related health decline. In the context of COPD, the BBSRC funds a small amount of directly underpinning biotechnology work on the development of new lung tissue models.</p><p> </p><p>2. The MRC supports investigator-led research in response to proposals from the academic community and does not normally allocate funds to particular topics. High quality applications for support are welcomed into any aspect of human health and are judged in open competition with other demands on funding. Awards are made according to their scientific quality and importance to human health. The MRC also provides long term funding through our own research Units, often in partnership with Universities. In addition to research directly relating to the development of new drugs and treatments for COPD the MRC also supports a broader portfolio of research on COPD and other respiratory conditions which aims to advance our understanding and inform new treatments.</p><p> </p><p>3. The Science and Technology Facilities Council (STFC) has not funded any research into the development of new drugs and treatments for COPD. STFC’s Central Laser Facility and the Diamond Light Source have provided access for research by other organisations.</p><p> </p><p>4. Total spend by the NIHR on research relating to the development of new drugs and treatments for COPD is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these topics cannot be disaggregated from total CRN expenditure.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2015-03-25T12:56:06.617Zmore like thismore than 2015-03-25T12:56:06.617Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4026
label Biography information for Liz Kendall more like this